Evidence map›Paper›PMID 34496877›Full record

ArticleJournal of nanobiotechnology2021

A dual-quenched ECL immunosensor for ultrasensitive detection of retinol binding protein 4 based on luminol@AuPt/ZIF-67 and MnO

Wei Gong, Suqing Yang, Fen Zhang, Fengshun Tian, Junman Chen, Zhigang Yin, Shijia Ding, Wei Yang, Rong Luo

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Au-g-CJournal of nanobiotechnology · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Wei Gong *Medical Examination Centre, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Suqing Yang *Chongqing Testing & Lnspection Center for Medical Devices, Chongqing, 400016, China.
Fen ZhangMedical Examination Centre, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Fengshun TianMedical Examination Centre, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Junman ChenKey Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, China.
Zhigang YinKey Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, China.
Shijia DingKey Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, China.
Wei YangKey Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, China. yang623621810@163.com.
Rong LuoMedical Examination Centre, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. luorongy@163.com.
Chongqing Medical University · CNFirst Affiliated Hospital of Chongqing Medical University · CN

Funding

national natural science foundation of china 81873980national science and technology major project of the ministry of science and technology of china 2018ZX10732202
6 · The paper itself

Abstract

backgroundRetinol binding protein 4 (RBP4) has been regarded as an important serological biomarker for type 2 diabetes mellitus (T2DM). Hence, the construction of a highly sensitive detection method for RBP4 is the key to early prevention and multidisciplinary intervention of T2DM. In this work, a dual-quenched electrochemiluminescence (ECL) immunosensor has been fabricated for ultrasensitive detection of RBP4 by combining zeolitic imidazolate framework-67/AuPt-supported luminol (luminol@AuPt/ZIF-67) with MnO

resultsAuPt/ZIF-67 hybrids with high-efficiency peroxidase-like activity could provide multipoint binding sites for luminol and antibodies and significantly boost the amplified initial signal of the ECL immunosensor. Upon glutathione/H

conclusionsBenefiting from the above-mentioned properties, the designed immunoassay sensitivity exhibited excellent sensitivity and relative stability for RBP4 detection range from 0.0001 to 100 ng mL

Indexed as

Electrochemical TechniquesGoldHumansImmunoassayLimit of DetectionLuminescent MeasurementsLuminolManganese CompoundsMetal-Organic FrameworksNanocompositesNanotubes, CarbonOxidesPlatinumReproducibility of ResultsRetinol-Binding Proteins, PlasmaGoldLuminolManganese Compoundsmanganese oxideMetal-Organic FrameworksNanotubes, CarbonOxidesPlatinumRBP4 protein, humanRetinol-Binding Proteins, PlasmaElectrochemiluminescence resonance energy transferLuminolMnO2 nanosheetsRetinol binding protein 4Zeolitic imidazolate framework-67

Identifiers

PMID34496877
PMCPMC8425071
OpenAlexW3197258781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.